Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Market Closed - Nasdaq Other stock markets 16:00:00 2026-03-13 EDT			5-day change	1st Jan Change
92.36 ^USD	-3.21%		+0.29%	+5.75%

03-12	Protagonist Therapeutics, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-12-2026 11:30 AM
03-02	Takeda and Protagonist Therapeutics, Inc Announce FDA Accepts Priority Review for First-In-Class Therapy Rusfertide in Polycythemia Vera	CI

Transcript : Protagonist Therapeutics, Inc. - Special Call

Published on 06/02/2025 at 02:20 pm EDT - Modified on 06/16/2025 at 03:20 pm EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Welcome to the Protagonist Therapeutics June 2 Conference Call. [Operator Instructions]. As a reminder, this call is being recorded today, Monday, June

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Protagonist Therapeutics, Inc.

03-12	Protagonist Therapeutics, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-12-2026 11:30 AM
03-02	Takeda and Protagonist Therapeutics, Inc Announce FDA Accepts Priority Review for First-In-Class Therapy Rusfertide in Polycythemia Vera	CI
03-02	Wedbush Raises Price Target on Protagonist Therapeutics to $100 From $86, Keeps Outperform Rating	MT
03-02	Takeda, Protagonist Say FDA Accepts New Drug Application for Potential Polycythemia Vera Treatment	MT
02-25	Earnings Flash (PTGX) Protagonist Therapeutics, Inc. Reports Q4 Revenue $7.4M	MT
02-25	Protagonist Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
01-28	Protagonist Therapeutics Insider Sold Shares Worth $4,063,743, According to a Recent SEC Filing	MT
01-13	Protagonist Therapeutics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 08:15 AM
01-05	Takeda and Protagonist Announce Submission of New Drug Application for Rusfertide for Treatment of Polycythemia Vera	CI
01-05	Truist Adjusts Price Target on Protagonist Therapeutics to $110 From $88, Maintains Buy Rating	MT
01-05	Takeda Pharmaceutical, Protagonist Submit FDA Application for Rusfertide for Polycythemia Vera Treatment	MT
12-06	Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Present Longer-Term Data At ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera	CI
11-06	Protagonist Therapeutics Q3 net loss widens to $39.3 mln	RE
11-06	Earnings Flash (PTGX) Protagonist Therapeutics, Inc. Reports Q3 Revenue $4.7M, vs. FactSet Est of $3.8M	MT
11-06	Protagonist Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI